Tag: clinical trials
-
Safety, Activity Assessed in New Duchenne Drug
25 January 2016. An early-stage clinical shows an experimental drug for Duchenne muscular dystrophy is safe for patients and produces the desired chemical activity in the body. Results of the trial, conducted by Catabasis Pharmaceuticals were released today. The Cambridge, Massachusetts company says it is now extending the study to test the drug against a…
-
MD Anderson, AbbVie Partner on Immunotherapies
22 January 2016. MD Anderson Cancer Center and pharmaceutical company AbbVie are collaborating on new treatments for cancer than harness the body’s immune system. Financial and intellectual property aspects of the three-year partnership were not disclosed. MD Anderson is part of the University of Texas system in Houston. The agreement gives AbbVie, in Chicago, access…
-
Trials Show Safety, Benefit of Stem Cells to Treat ALS
11 January 2016. Two clinical trials testing stem cells to treat amyotrophic lateral sclerosis, or ALS, found the treatments are safe for patients, and can slow progression of the disease. Results of the trials testing the stem cell product known as NurOwn made by BrainStorm Cell Therapeutics in Petach Tikvah, Israel are reported today in…
-
Grünenthal Group to Commercialize Duchenne Therapy
8 January 2015. Grünenthal Group, a German pharmaceutical company, is licensing a treatment candidate for Duchenne muscular dystrophy developed by Akashi Therapeutics, a biopharmaceutical company created by organizations advocating for research on the disease. While full financial details of the agreement were not disclosed, Grünenthal says it’s committing more than $100 million to the venture.…
-
Electronic Stimulation Shown to Reduce Arthritic Knee Pain
5 January 2015. Results from a clinical trial show a device emitting electronic pulses reduced more pain in the knees of people with osteoarthritis, compared to a placebo. Findings from the study, conducted by a team from University of Messina in Italy, appear in the January 2016 issue of the journal Rheumatology. The trial tested…
-
Clinical Trials to Test Artificial Pancreas
4 January 2016. Two new clinical trials are planned to test a smartphone-based closed-loop artificial pancreas system for people with type 1 diabetes. The system is developed by teams at University of Virginia in Charlottesville and Harvard University, and licensed for commercial development by TypeZero LLC, also in Charlottesville. The trials are funded by a…
-
Trial Underway Testing Preterm Respiratory Treatment
30 December 2015. A clinical trial testing new treatment methods for a common respiratory disorder faced by preterm babies began enrolling patients. The trial is testing an aerosol-delivered surfactant, a wetting agent applied to the lungs of babies born prematurely without natural surfactants to keep open air sacs in lungs, made by Discovery Laboratories a biotechnology…
-
Trial Shows Vaccine Protects Against Stem Cell Complications
24 December 2015. An early-stage clinical trial indicates a vaccine protects against complications from stem cell transplants used to treat blood-related cancers. Results of the trial conducted by City of Hope medical center in Duarte, California that developed the vaccine appear online in the journal The Lancet Haematology (paid subscription required), and were discussed earlier…
-
Trial Shows Clot Prevention Drug Safe, Reversible
18 December 2015. An early-stage clinical trial of an experimental drug to prevent blood clots during heart surgery shows the drug prevents platelet accumulation, while still safe and temporary to prevent excess bleeding. The study by a team at Tufts University Medical Center in Boston and Sinai Hospital of Baltimore appears in yesterday’s issue of…
-
Galapagos Licensing Inflammation Drug in $2.1B Deal
17 December 2015. A biotechnology company is licensing its small molecule drug for treating inflammatory disorders to the biopharmaceutical company Gilead Sciences in a deal valued at nearly $2.1 billion. The agreement includes Gilead Sciences taking an ownership stake in Galapagos NV, based in Mechelin, Belgium. The deal involves the small-molecule, or low molecular weight,…